880160-63-4

Upstream product

• 391-92-4 methyl 5-fluoro-2-hydroxybenzoate 
• 67-56-1 methanol 
• 130046-91-2 5-fluoro-2-hydroxy-3-nitrobenzoic acid 

Downstream Products

• 880160-70-3 methyl 5-fluoro-3-nitro-2-(((trifluoromethyl)sulfonyl)oxy)benzoate 
• 1408282-26-7 6-fluoro-3,10-diazatricyclo[6.4.1.0^4,13]trideca-1,4⁽¹³⁾,5,7-tetraen-9-one 
• 1175529-01-7 methyl 3-amino-5-fluoro-2-hydroxybenzoate 

Relevant academic research and scientific papers

WDR5-MYC INHIBITORS

Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Method for preparing intermediate for drug for treating ovarian cancer

The invention belongs to the technical field of chemical drugs, and particularly relates to a method for preparing an intermediate for a drug for treating ovarian cancer. According to the method, zirconium n-butoxide and ferric chloride serve as raw mater

Preparation method of key intermediate 1408282-26-7 of ovarian cancer resisting drug Rucaparib

The invention discloses a preparation method of a key intermediate 1408282-26-7 of an ovarian cancer resisting drug Rucaparib, and relates to preparation of medical intermediates. The preparation method comprises the following steps: reacting a compound 1 with potassium nitrate to obtain a compound 2; reacting the compound 2 with trimethylsilylacetylene to obtain a compound 3; reacting the compound 3 with hydrogen to obtain a compound 4; carrying out self cyclization on the compound 4 to obtain a compound 5; reacting the compound 5 with nitroethylene to obtain a compound 6; reacting the compound 6 with the hydrogen to obtain the key intermediate 1408282-26-7 of the ovarian cancer resisting drug Rucaparib. The method has the advantages that nitro-sulfuric acid mixed nitration reaction and the discharge of wastewater and waste gas are avoided, safe production is ensured, and safety and environment friendliness are realized; raw materials are easy to obtain and low in price and cost, thereby facilitating industrial production; the reaction yield is greatly improved, the reaction route is optimized, the product purification steps are simplified and the industrial production is facilitated.

BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) or Formula (II): wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

Method of preparing poly(ADP-ribose) polymerases inhibitors

This invention relates to a new and convergent route to small molecule inhibitors of poly(ADP-ribose) polymerase, such as 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, via a key Sonogashira coupling reaction and a CuI-promoted indole formation.